Better Cancer Outcomes Possible with Imagin Medical Inc. (CSE: IME) (OTCQB: IMEXF) Technology

February 26, 2021 12:16:56
  • Imagin Medical Inc.’s patented i/Blue System revolutionizes the way surgeons are able to visualize the bladder and identify cancers during surgery
  • The breakthrough technology of Imagin Medical’s i/Blue Imaging System rectifies the limitations of both white and blue light cystoscopies
  • Bladder cystoscopies first target – multiple other endoscopic procedures planned

Science and technology have continued to make striking advancements in cancer therapeutics and treatment protocols, improving upon on past successes and creating better outcomes for cancer patients. A prime example is an exciting new development in visualizing cancer during minimally invasive surgeries. Surgical imaging company Imagin Medical (CSE: IME) (OTCQB: IMEXF), is establishing a new paradigm in a doctor’s ability to “see” and surgically treat cancers. With bladder cancer as its first target, Imagin Medical’s initial product is the i/Blue Imaging™ System. The company’s patented, ultrasensitive imaging technology is based on advanced optics and light sensors and employs ultrasensitive imaging technology. Identifying potential early-stage tumors can be difficult because of the inability to distinguish between healthy tissue and tumors when viewed through a scope only using conventional white light.

Cystoscopy is the conventional diagnostic procedure for visualizing bladder cancer during surgery. It allows the doctor to see inside the body with a thin, lighted, flexible tube called a cystoscope which uses white light to illuminate the bladder. White light has been used for decades and is the standard for more than 90% of the market. Like a roadmap with street signs, white light images show the full landscape of the bladder but do not effectively highlight cancer. A promising new modality, blue light cystoscopy, uses blue-filtered white light to detect flat tumors and cancerous cells not seen with white light that may be left behind during surgical removal of the tumor. However, surgeons can’t operate using blue light images. The blue images aren’t in real time, orientation in the bladder is easily lost and the surgeon must manually switch from white to blue cystoscopy and back again.

Both white and blue light cystoscopies have effective uses and serious limitations in seeing the landscape of the bladder and identifying all the cancerous cells during surgery. Missing any cancerous cells poses serious concerns because they will continue to grow and spread to other parts of the bladder, a fact reflected by the recurrence rate of fifty per cent.

The breakthrough technology of Imagin Medical’s i/Blue Imaging System rectifies the limitations of both white and blue light cystoscopies. By combining the white and blue light with an FDA-approved imaging agent, the i/Blue System displays side-by-side images in real-time, without the necessity to switch back and forth between the two images. Unlike any other modalities on the market today, Imagin Medical’s i/Blue Imaging System can attach to almost any endoscope model currently in use which creates a plug and play state-of-the-art system adaptable to virtually any clinical setting.

Imagin Medical is advancing the i/Blue Imaging System toward commercialization. The FDA approval process is underway, and the company’s intellectual property is well-protected. Perhaps even more significant, Imagin intends to build on the i/Blue technology which will facilitate entry into multiple other endoscopic procedures. Imagin Medical is improving on past technologies and creating better outcomes for patients while even at a reduced cost.

For more information, visit the company’s website at

NOTE TO INVESTORS: The latest news and updates relating to IMEXF are available in the company’s newsroom at

About BioMedWire

BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published:

BioMedWire (BMW)
San Francisco, California
415.949.5050 Office

BioMedWire is part of the InvestorBrandNetwork.